hrp0094p2-72 | Bone, growth plate and mineral metabolism | ESPE2021

ACAN gene skeletal dysplasia (short size syndrome, with or without advanced bone age and early onset osteoarthritis)

Aguilar Riera Cristina , Arciniegas Larry , Murillo Valles Marta , Ros Pena Andrea , Alvarez Paula Fernandez , Clemente Maria , Yeste Diego ,

Aggrecan is a structural glycoprotein of the extracellular matrix of cartilage present in the articular cartilage, growth plate and cartilage of the intervertebral disc. Biallelic pathogenic variants are the cause of aggrecan type spondyloepiphyseal dysplasia (OMIM#612813) while the presence of heterozygous pathogenic variants determine Kimberley type spondyloepiphyseal dysplasia (OMIM#608361) and short stature associated or not with acceleration of bone maturation and early o...

hrp0097t14 | Section | ESPE2023

Circulating Progranulin in Human Infants: Relation to Prenatal Growth and Early Postnatal Nutrition

Díaz Marta , Mestres-Arenas Alberto , López-Bermejo Abel , de Zegher Francis , Villarroya Francesc , Ibáñez Lourdes

Background: Progranulin (PGRN) displays pleiotropic biological functions including on early embryogenesis, cell proliferation, lysosomal or neuronal functioning and wound repair, and has been proposed as a biomarker for metabolic diseases. Increased PGRN levels have been reported in type 2 diabetes, nonalcoholic fatty liver disease and in preeclampsia associated to placental dysfunction. However, the ontogeny of PGRN concentrations and the potential value of P...

hrp0097p1-506 | Growth and Syndromes | ESPE2023

Characteristics, effectiveness and safety data for patients with growth failure treated with recombinant IGF-1 and achieving adult or near-adult height: results from the Increlex® Global Registry

Bang Peter , Ramón Krauel Marta , Maghnie Mohamad , Woelfle Joachim , Sert Caroline , Perrot Valérie , Pennestri Daniele , Polak Michel

Background: severe primary insulin-like growth factor-1 deficiency (SPIGFD) is a rare growth disorder. Recombinant human insulin-like growth factor (IGF-1) (rhIGF-1; Increlex® [mecasermin]) replacement therapy is EU and US-approved for treating growth failure due to SPIGFD. The long-term therapeutic objective of rhIGF-1 treatment in SPIGFD is to improve adult height (AH). Objective: to describe the characteristics, safety and effectiveness data ...

hrp0097p2-52 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Patient with ABCD syndrome (Abnormal Calcium, Calcinosis, Creatinine in Down syndrome), a rare cause of pediatric hypercalcemia

Lucia Feller Ana , Aziz Mariana , Gil Silvia , Quarracino Malena , Mendoza Lincolns , Paz Marcos , Vaiani Elisa , Ciaccio Marta , Viterbo Gisela

Introduction: ABCD syndrome is characterized by hypercalcemia, hypercalciuria, nephrocalcinosis, and renal impairment, generally under 4 years old. This is a rare cause of pediatric hypercalcemia with only 7 cases published, but it is believed to be underdiagnosed. The suspected mechanism would be associated with overexpression of transient receptor potential channels (TRP) that modulate intestinal absorption of calcium, since TRP-M2 is encoded on chromosome 2...

hrp0097p2-151 | Thyroid | ESPE2023

Congenital hypothyroidism in children with Sotos syndrome

Cavarzere Paolo , Munari Stefania , Raitano Vincenzo , Gaudino Rossella , Nicolussi Principe Lara , Arrigoni Marta , Zoller Thomas , Antoniazzi Franco

Background: Congenital Hypothyroidism (CH) is the most common neonatal endocrinologic disorder and one of the most preventable causes of mental retardation and neurological alterations in children. The incidence of CH lies between 1 in 2000-3000 newborns. The replacement therapy with levothyroxine (LT4) should be started immediately since studies show that a rapid normalization of TSH and fT4 optimizes the neurodevelopmental outcome. Infants with Down syndrome...

hrp0097p2-272 | Late Breaking | ESPE2023

Is screening for vitamin D deficiency reasonable or should we supplement at risk patients?

Oliveira Mariana , Cláudia Moura Ana , Miguel Cláudia , Pinto Mariana , Barros Marta , Almeida Nuno , Adriana Rangel Maria

Introduction: No consensus on vitamin D (VitD) deficiency screening in children and adolescents exists.Aim: To evaluate a sample of patients in whom VitD dosing was performed and determine the rationale for this assessment.Methods: Retrospective, longitudinal study of pediatric patients, from a Portuguese tertiary hospital, who had at least two 25(OH)D level blood sampling between ...

hrp0098rfc11.2 | Fat, Metabolism and Obesity 2 | ESPE2024

Is the Single Point Insulin Sensitivity Estimator (SPISE) index a reliable tool for children and adolescents with overweight/obesity?

Tantari Giacomo , Bassi Marta , Pistorio Angela , Minuto Nicola , Napoli Flavia , Piccolo Gianluca , Spacco Giordano , d'Annunzio Giuseppe , Maghnie Mohamad

Introduction: Pediatric obesity is is increasing worldwide. Children and adolescents affected are at increased risk of Type 2 Diabetes Mellitus and its cardiovascular complications, starting in young adulthood and linked to insulin resistance and its inflammatory milieu. The SPISE index, calculated using baseline triglycerides, HDL cholesterol, and BMI, shows promise in predicting insulin resistance in this population. It is not affected by insulin secretion p...

hrp0098p1-22 | Diabetes and Insulin 1 | ESPE2024

Clinical and molecular spectrum of polycystic kidney syndrome and diabetes due tomutations in hnf-1b

Salamanca Fresno Luis , Melgosa Hijosa Marta , Gomes Porras Mariana , González Casado Isabel , Campos Barros Ángel

Introduction: Polycystic kidney and diabetes syndrome (PCKDD) is an autosomal dominantly inherited disorder caused by HNF-1B mutations associated with a heterogeneous multisystemic phenotype mainly affecting kidney and pancreas, resulting in highly variable nephropathies, and frequently, diabetes diagnosed before the age of 25 yrs. Pancreatic hypoplasia, malformations in the genital tract and hepatic dysfunction may also be observed.<str...

hrp0098p1-63 | Growth and Syndromes 1 | ESPE2024

Long-term effectiveness and safety data from the Global Increlex® Registry in patients treated with rhIGF-1: Subgroup analysis of naïve pre-pubertal patients and patients with Laron syndrome

Ramón Krauel Marta , Woelfe Joachim , Polak Michel , Maghnie Mohamad , Beń-Skowronek Iwona , Sert Caroline , Perrot Valérie , Bang Peter

Background: The Global Increlex® Registry (NCT00903110) monitors real-world safety and effectiveness of recombinant human insulin-like growth factor (rhIGF-1; Increlex® [mecasermin]) in severe primary IGF-1 deficiency (SPIGFD). Patient characteristics, effectiveness and safety data from 2008–2023 are described.Methods: Descriptive analyses of registry data from children/adolescents age...

hrp0098p1-132 | Fat, Metabolism and Obesity 2 | ESPE2024

The proteome of circulating exosomes in appropriate- versus small-for-gestational-age infants: differentially expressed proteins at birth associate with measures of weight gain, liver fat, insulin resistance and adrenarche at age 7

Díaz Marta , Quesada Tania , Villarroya Francesc , López-Bermejo Abel , Casano Paula , de Zegher Francis , Ibáñez Lourdes

Introduction: Exosomes are extracellular vesicles whose cargo includes proteins that may influence the function of distant cells. It is unknown, however, whether there are differentially expressed proteins (DEPs) in the circulating exosomes of appropriate- vs small-for-gestational-age (AGA vs SGA) infants at birth and, if so, whether such DEPs relate to measures of endocrine-metabolic health and body composition in childhood.Subj...